|
Name |
Actinoallolide D
|
| Molecular Formula | C32H52O7 | |
| IUPAC Name* |
(5R)-12-ethyl-8,10-dimethyl-5-[(2R,3R,4R,8S,9R,10R,11S)-3,9,11-trihydroxy-4,6,8,10-tetramethyltridec-6-en-2-yl]-4,13-dioxabicyclo[8.2.1]trideca-1(12),7-diene-3,11-dione
|
|
| SMILES |
CCC1=C2CC(=O)O[C@H](CC=C(CC(C1=O)(O2)C)C)[C@H](C)[C@@H]([C@H](C)CC(=C[C@H](C)[C@H]([C@H](C)[C@H](CC)O)O)C)O
|
|
| InChI |
InChI=1S/C32H52O7/c1-10-24-27-16-28(34)38-26(13-12-18(3)17-32(9,39-27)31(24)37)23(8)30(36)21(6)15-19(4)14-20(5)29(35)22(7)25(33)11-2/h12,14,20-23,25-26,29-30,33,35-36H,10-11,13,15-17H2,1-9H3/t20-,21+,22+,23-,25-,26+,29+,30+,32?/m0/s1
|
|
| InChIKey |
FRIXVASHXAKYRS-LLAZDTPNSA-N
|
|
| Synonyms |
Actinoallolide D
|
|
| CAS | NA | |
| PubChem CID | 156580455 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 548.7 | ALogp: | 5.6 |
| HBD: | 3 | HBA: | 7 |
| Rotatable Bonds: | 11 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 113.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 39 | QED Weighted: | 0.226 |
| Caco-2 Permeability: | -4.748 | MDCK Permeability: | 0.00002020 |
| Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.989 |
| Human Intestinal Absorption (HIA): | 0.084 | 20% Bioavailability (F20%): | 0.285 |
| 30% Bioavailability (F30%): | 0.555 |
| Blood-Brain-Barrier Penetration (BBB): | 0.01 | Plasma Protein Binding (PPB): | 83.37% |
| Volume Distribution (VD): | 1.311 | Fu: | 5.94% |
| CYP1A2-inhibitor: | 0.036 | CYP1A2-substrate: | 0.072 |
| CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.823 |
| CYP2C9-inhibitor: | 0.023 | CYP2C9-substrate: | 0.045 |
| CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.032 |
| CYP3A4-inhibitor: | 0.744 | CYP3A4-substrate: | 0.638 |
| Clearance (CL): | 8.272 | Half-life (T1/2): | 0.415 |
| hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.967 |
| Drug-inuced Liver Injury (DILI): | 0.89 | AMES Toxicity: | 0.016 |
| Rat Oral Acute Toxicity: | 0.318 | Maximum Recommended Daily Dose: | 0.018 |
| Skin Sensitization: | 0.281 | Carcinogencity: | 0.097 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
| Respiratory Toxicity: | 0.434 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004260 | ![]() |
0.823 | D0WY9N | ![]() |
0.194 | ||
| ENC004261 | ![]() |
0.719 | D03KIA | ![]() |
0.193 | ||
| ENC004255 | ![]() |
0.609 | D06LNW | ![]() |
0.190 | ||
| ENC004257 | ![]() |
0.600 | D0Y7LD | ![]() |
0.177 | ||
| ENC003822 | ![]() |
0.284 | D03SVX | ![]() |
0.176 | ||
| ENC003155 | ![]() |
0.279 | D00FSV | ![]() |
0.176 | ||
| ENC003821 | ![]() |
0.276 | D0L5FY | ![]() |
0.175 | ||
| ENC005126 | ![]() |
0.267 | D04QST | ![]() |
0.173 | ||
| ENC002889 | ![]() |
0.255 | D0W2EK | ![]() |
0.173 | ||
| ENC002777 | ![]() |
0.252 | D0L7AS | ![]() |
0.172 | ||